US2020095305A1PendingUtilityA1
Methods of modulating immune responses using bcma polypeptide
Est. expiryAug 17, 2019(expired)· nominal 20-yr term from priority
Inventors:Jeffrey BrowningChristine AmbroseFabienne MackayJurg TschoppPascal SchneiderJeffrey Thompson
A61K 38/17C07K 14/7151A61P 7/06C07K 16/241C07K 2319/00A61P 29/00A61P 7/00A61P 35/02A61P 43/00A61P 9/12A61K 2039/505A61P 21/04C07K 14/70575A61P 35/00A61K 39/395A61P 9/00A61P 37/06C07K 14/715A61P 37/00A61P 37/02A61P 9/10A61P 31/18A61P 17/00A61P 13/12A61K 39/00A61K 47/68A61K 38/1793
76
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
Claims
exact text as granted — not AI-modified1 - 21 . (canceled)
22 . A method of treating a renal disorder in a mammal, the method comprising the step of administering to the mammal an effective amount of a BCMA (B-Cell Maturation Antigen) polypeptide, wherein the BCMA polypeptide comprises an amino acid sequence that binds to BAFF (B-Cell Activating Factor of the TNF family; SEQ ID NO:9) and is:
a) at least 95% identical to amino acids 1-51 of SEQ ID NO:1; or b) at least 95% identical to amino acids 8-41 of SEQ ID NO:1.
23 . The method of claim 22 , wherein the BCMA polypeptide comprises an Fc domain of an immunoglobulin.
24 . The method of claim 22 , wherein the mammal is human.
25 . The method of claim 22 , wherein the BCMA polypeptide comprises the sequence of amino acids 1-51 of SEQ ID NO:1.
26 . The method of claim 22 , wherein the BCMA polypeptide comprises the sequence of amino acids 8-41 of SEQ ID NO:1.
27 . The method of claim 23 , wherein the immunoglobulin is IgG.
28 . The method of claim 23 , wherein the immunoglobulin is human.Join the waitlist — get patent alerts
Track US2020095305A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.